%0 Generic
%A Manso, L
%A Ciruelos, E
%A Codes, M
%A De la Haba, J
%A Galan, A
%A Baena, J
%A Jaen, A
%A Gil, M
%A Murias, A
%A Blancas, I
%A Gonzalez, E
%A Perez, D
%A Bayo, JL
%A Mel, J
%A Garcia-Martinez, E
%A Cubedo, R
%A Salvador, J
%T Prognostic value of a high level of circulating endothelial cells in  patients with HER2-recurrent or metastatic breast cancer treated  with bevacizumab in combination with paclitaxel and gemcitabine  as fi  rst-line therapy
%D 2011
%@ 1465-5411
%U http://hdl.handle.net/10668/2231
%X Circulating endothelial cells (CECs) are shed from vessels and enter the circulation reflecting endothelial damage. Increased numbers of CECs have been documented in cancer, and appear to correlate with progression of the tumor. Bevacizumab (B) in combination with CT improves progression-free survival (PFS) of first-line treatments and may modify tumor cell intravasation and CEC/CTC levels.
%K Neoplasias
%K Bevacizumab
%K Anticuerpos monoclonales humanizados
%K Desoxicitidina
%K Progresión de la enfermedad
%K Células endoteliales
%K Paclitaxel
%~